Zymo Research and Hamilton Robotics have agreed an ongoing collaboration that teams Zymo Research’s DNA methylation detection and quantitation products and RNA and DNA extraction products with Hamilton’s high-throughput automation platforms.
Zymo Research has already created optimized methods for microbiomics and RNA isolation for use on Hamilton’s automated liquid handling workstations, including a timesaving and robust automated method for non-biased extraction of DNA and RNA.
Additional integrated workflow methods will be released to the academic, biopharma and diagnostics markets in the future.
Epigenetics may hold important keys to unlocking a myriad of diseases and disorders, such as cancer, autism, Alzheimer’s, and addictions. Stratistics Market Research Consulting, in a recent market research study conducted by them, says that the global epigenetics market is expected to reach $1,286 million by 2022 growing at arate of 14 per cent from 2015 to 2022.
According to Marc Van Eden, Vice President of Business Development at Zymo Research, “Understanding the role of epigenetic mechanisms in the regulation of gene expression is an emerging field. By combining Zymo Research’s epigenetics expertise with Hamilton Robotics automated systems, researchers are able to automate routine, mundane tasks leading to fewer errors and more efficient workflows.”
Debbie Bowers, Vice President of Robotic Operations at Hamilton Robotics agrees, “Especially in diagnostics, epigenetics methods are transitioning into higher throughputs and sequencing, but this doesn’t have to be a complex situation. Our strategic partnership with Zymo Research allows researchers to assimilate quickly with an optimized and robust solution, without unknowns or time-consuming delays, so they are up and running quickly.”